Multimorbidity in Finnish and Swedish speaking Finns; association with daily habits and socioeconomic status - Nordic EpiLung cross-sectional studyShow others and affiliations
2021 (English)In: Preventive Medicine Reports, E-ISSN 2211-3355, Vol. 22, article id 101338
Article in journal (Refereed) Published
Abstract [en]
Multimorbidity is an emerging public health priority. This study aims to assess the role of lifestyle and socioeconomic status in the prevalence of multimorbidity and chronic diseases by using two language groups that are part of the same genetic subgroup but differ by daily habits. We conducted a cross-sectional survey in 2016 with randomly selected population sample with 4173 responders (52.3%) aged 20-69 years in Western Finland. We included 3864 Finnish participants with Swedish (28.1%) or Finnish (71.9%) as a native language. We used a questionnaire to assess participants' chronic diseases and lifestyle. We determined multimorbidity as a disease count ≥2.
Finnish speakers were more likely to have a diagnosis of COPD, heart failure, diabetes, reflux disease, chronic kidney failure, and painful conditions than Swedish speakers. The prevalence of multimorbidity was higher for Finnish speakers in the age group of 60-69 years (41.0% vs. 32.0%, p=0.018) than Swedish speakers. A higher proportion of Finnish speakers smoked, were obese, inactive, and had lower socioeconomic status compared to Swedish speakers. All these factors, in addition to age and female sex, were significant risk factors for multimorbidity. Prevalence of multimorbidity was different in two language groups living in the same area and was associated with differences in lifestyle factors such as smoking, physical inactivity and obesity.
Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 22, article id 101338
Keywords [en]
Multimorbidity, Risk factors, Health disparities, COPD, Obesity
National Category
Nursing
Research subject
Nursing
Identifiers
URN: urn:nbn:se:ltu:diva-83087DOI: 10.1016/j.pmedr.2021.101338ISI: 000659961900041PubMedID: 33732608Scopus ID: 2-s2.0-85103260737OAI: oai:DiVA.org:ltu-83087DiVA, id: diva2:1531614
Note
Godkänd;2021;Nivå 0;2021-03-22 (alebob);
Finansiär: Tampere Tuberculosis Foundation; The Finnish Anti-Tuberculosis Association Foundation; The Research Foundation of The Pulmonary Diseases; The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital; The Medical Research Fund of Seinäjoki Central Hospital
2021-02-262021-02-262025-04-16Bibliographically approved